Cash Strategies for Life Sciences Delays
By Andrew Levitch
The one constant when raising financing in a life sciences company is that it takes longer than initially forecasted. As previously shared in my colleague Patrick Nugent’s article about Life Sciences Financing Trends, it is taking twice as long to close a financing round (six months or more), and the length of time…Read More
Read MoreHow to Successfully Extend the Cash Runway to Growth in Early Commercial Stage Life Science Companies
By Andrew Levitch, Patrick Nugent
This article is the second in a 4-part series reviewing financing solutions for the Life Science sector. Life Science venture capital and private equity-funded startups are constantly chasing capital to extend operating cash runways, driving value inflection milestones such as clinical trial data and funding growth for commercial-stage entities. Understandably,…Read More
Read MoreTrends in Financing in Life Sciences: 2024 Updates
By Patrick Nugent
This article is first in a 4-part series reviewing financing solutions for the Life Science sector. As we move into Q2 of 2024, the Fed continues to hold the line on interest rate declines. Capital markets remain tight and for companies in need of growth financing, this is problematic. This…Read More
Read More